For sponsors developing non-GLP-1 peptide programmes in oncology, rare disease, or other therapeutic areas, the competition for the same SPPS reactor capacity, the same HPLC purification infrastructure, and the same analytical characterisation capability has materially lengthened lead times and elevated costs
After NaB administration, FBG levels in diabetic mice were significantly reduced (Fig
Inside, carnitine palmitoyltransferase II (CPT II) releases the fatty acid from L-carnitine so it can produce energy through -oxidation [6]
Angelova-Fischer I, Rippke F, Fischer TW, Neufang G, Zillikens D
MedPal AI, which took over the running of two insolvent distance-selling pharmacies last year, announced yesterday (May 20) that its New Health brand seeks to capitalise on rapid growth in the market for GLP-1s and broader peptide medicines
Differential expression of micro RNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients